We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kymab

News List

Sanofi to acquire Kymab for up to $1.45bn pharmatimes
January 12, 2021
Sanofi will acquire Cambridge, UK-based biopharmaceutical company Kymab in a potential $1.45bn deal, which will see the French pharma add Kymab’s monoclonal antibody (mAB) KY1005 to its pipeline.
Kymab wins UK court case against Regeneron’s patent claims europeanpharmaceuticalreview
June 30, 2020
The UK Supreme Court has ruled that Regeneron’s patent claim regarding genetically modified mice against Kymab are invalid.
Kymab announces Merck exec Simon Sturge as new CEO pharmafile
April 11, 2019
Kymab announces Merck exec Simon Sturge as new CEO.
Kymab, Roche Partner to Evaluate KY1044 contractpharma
July 03, 2018
Kymab Group Ltd has entered a clinical trial agreement with Roche. Under the agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination in Kymab’s upcoming Phase I-II clinical studies combining